Contents Vol. 217, 2008
Luigi Naldi(Centro Studi GISED), Zenus Saleh, Laurent Tisseau, Eugenia Caggese, Emmanuel Laffitte(Hôpital Beau-Séjour), Takeshi Nakajima(Osaka International Cancer Institute), Paola Bertuccio, María Jones‐Caballero, Thomas Bieber(CK-CARE), Hitoshi Iyatomi, Gilles Safa, Alberto Giannetti(University of Modena and Reggio Emilia), Uta Schwanebeck, Gabriella Mendes Duarte, Antonio Addis(University of Toronto), Thomas Ruzicka(Ludwig-Maximilians-Universität München), Shigeki Inui(University of Rochester Medicine), Mirjana Urosevic, Michael J. Meurer(Boston University), Dagmar Wilsmann‐Theis(University Hospital Bonn), Benoît Bensaïd(Hospices Civils de Lyon), Xina Grählert, Carlo Tomino, Alexander Vasilevic Kuznetsov, Thierry Simonart(IS practice), Patrick A. Oberholzer(Sanofi (United States)), M. Loppin, Masaru Tanaka, Liliane Chatenoud(Mario Negri Institute for Pharmacological Research), Maria Rita Bongiorno(University of Palermo), Masayuki Kimoto, Hans C. Steinert(University of Zurich), Jochen Schmitt(University Hospital Carl Gustav Carus), Mauro Picardo(Istituto Dermopatico dell'Immacolata), Natalija Novak(University Hospital Bonn), Luca Borradori(University Dermatology), Knut Schäkel(Heidelberg University), Sonja Molin, J. Lamoril(Hôpital Bichat-Claude-Bernard), Peter Weisenseel, Reinhard Dummer(University Hospital of Zurich), Michiie Sakamoto(Keio University), Mara Maccarone, Renato G. Panizzon, Sergio Chimenti(University of Milan), Rosanna Cuscito, Mario Aricò(University of Palermo), O. Lejeune, Satoshi Itami, Yuri Nogueira Chaves
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
The Global Burden of Cancer 2013
|JAMA Oncology|2015|2.8k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k